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Based on evidence that granulocyte-macrophage col-
ony stimulating factor (GM-CSF) induces a potent
systemic antitumor immunity, we tested recom-
binant GM-CSF in advanced melanoma. Seven
patients with histologically con®rmed cutaneous
melanoma metastases were treated with perilesional
intracutaneous injections of recombinant GM-CSF
and observed for a follow-up time of 5 y. All but
two patients had a decrease in the total number of
metastases. At the end of the 5 y follow-up three of
the seven patients are still alive with only one patient
receiving other than surgical therapy, and one
patient died tumor free at the age of 93. The remain-
ing three patients died from progressive melanoma.
Perilesional intradermal GM-CSF therapy resulted in
a mean survival time of 33 mo. The treatment was
well tolerated and no side-effects other than local
erythema at the injection sites and mild drowsiness
were seen. Immunohistochemical analysis with stain-
ing for CD14 and GM-CSF receptor demonstrated
an increased in®ltration of monocytes into both
injected and noninjected cutaneous melanoma
metastases compared with lesions excised prior to
the initiation of therapy. The same was true for
CD4- and CD8-positive lymphocytes. This phe-
nomenon, together with GM-CSF-induced leukocyte
counts of more than 20,000 during therapy, support
the possible impact of a systemic over a locally
induced reaction by GM-CSF. To our knowledge
this is the ®rst report that intracutaneously injected
GM-CSF results in long-lasting reduction of mela-
noma metastases. Key words: granulocyte-macrophage
colony stimulating factors/melanoma/metastases/recombi-
nant/therapy. J Invest Dermatol 117:371±374, 2001
M
alignant melanoma is one of the most aggressive
human neoplasms. At present no effective treat-
ment exists for melanoma metastases and the
advanced disease is basically incurable and
associated with a mean survival of only 6 mo
(Itoh et al, 1992). Despite the grim prognosis of advanced
melanoma, spontaneous regression of primary and particularly of
secondary melanoma is a rare but well-known phenomenon
pointing towards immunologic host defense mechanisms (Avril
et al, 1992; Balch et al, 1992; Blessing and McLaren, 1992). These
defense mechanisms practically never result in long-term clinical
bene®t. Besides the classical tumor in®ltrating lymphocytes
(Rosenberg et al, 1986), cells of the monocyte-macrophage lineage
are the predominant cell type in®ltrating melanoma. Tumor-
associated macrophages have been shown both to promote and to
inhibit tumor growth, depending on their state of activation and on
the model system employed (Mantovani et al, 1992). GM-CSF was
shown to be the most effective molecule in inducing antitumor
reactivity (Dranoff et al, 1993). In this pilot study we therefore
tested the potential role of recombinant (r)-GM-CSF as a
therapeutic approach for patients with cutaneous melanoma
metastases.
MATERIALS AND METHODS
Eligibility Patients were required to have histologic proof of
cutaneous melanoma metastases, a Karnofsky scale greater than 60%, and
a life expectancy of more than 12 wk. Patients with brain metastases and
patients with a history of allergies or intolerance to exogenous protein
were excluded from the study. Seven melanoma patients with cutaneous
metastases met the eligibility criteria and were entered into the study. A
full medical history and physical examination, a cranial CT scan, a chest
X-ray, sonography of the lymph nodes, and a thorough evaluation of
hematologic and blood chemistry parameters were performed prior to
the initiation of treatment. Written informed consent was obtained from
all patients and the study was approved by the institutional ethics
committee. Standard WHO criteria were used for the evaluation of
response and toxicity (WHO, 1979).
Treatment A daily dose of 400 mg of r-GM-CSF (Leukomax,
Novartis) reconstituted with 1 ml of sterile water was administered
intradermally over 5 d at eight to ten sites around three to six cutaneous
metastases chosen as indicator lesions. After 21 d this treatment cycle was
repeated around the same lesions. Patients were monitored daily during
the injection periods, weekly until the end of the study (day 42), and
were routinely followed thereafter to a mean time of 59.7 6 1.6 mo.
Histologic and immunohistochemical analysis Metastatic
melanoma lesions were evaluated prior to the initiation of treatment and
after r-GM-CSF administration (injected lesions and noninjected lesions)
by standard hematoxylin and eosin histology and by immunohisto-
chemistry on paraf®n-embedded tissue for HMB 45 and on frozen
sections for GM-CSF receptor, CD4, CD8, and CD14. The antibodies
used were anti-HMB 45 (Dako, Carpinteria, CA) at a dilution of 1:50,
anti-GM-CSF receptor (Upstate Biotechnology, Lake Placid, NY) at a
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dilution of 1:200, anti-CD4 (Becton Dickinson, Mountain View, CA,
clone SK3/4) at a dilution of 1:100, anti-CD8 (Becton Dickinson, clone
SK2) at a dilution of 1:100, and anti-CD14 (Becton Dickinson, clone
Mo-P9) at a dilution of 1:100. Appropriate isotype controls were used.
Sections were incubated with the primary antibodies at the respective
dilutions for 1 h at room temperature and thereafter with biotinylated
horse antimouse antibody at a dilution of 1:200 for 1 h. Endogenous
peroxidase activity was blocked with 0.015% H2O2. The signal was
detected with the streptavidin-biotin-peroxidase method, and 3-amino-
9-ethylcarbazole was used as a chromogen. Slides were counterstained
with hematoxylin. The immunostaining intensity was rated as follows: ±,
none; +, weak; ++, moderate; +++, intense.
Follow-up proceedings After the end of the initial treatment period
(day 42) patients' follow-up consisted of routine blood screening and
radiologic restaging (either CT or chest X-ray plus abdominal
sonography) every 6 mo. No patient failed to turn up for the control
examinations during follow-up. No patient was lost to follow-up.
RESULTS
Patients' characteristics The patient characteristics of seven
melanoma patients with cutaneous metastases who met the
eligibility criteria are given in Table I. All had cutaneous/
subcutaneous metastases, none had visceral metastases, and three
had had lymph node metastases that had been removed by
lymphadenectomy.
Clinical response Each patient received two treatment cycles
with perilesionally, intracutaneously administered r-GM-CSF. This
treatment resulted in an initial size reduction of the injected
indicator lesion in six of seven patients. The total number of
cutaneous metastases was reduced in all but two patients and,
notably, there was a reduction of the number of metastases even if
the indicator lesion was not reduced in size, demonstrating a
therapeutic effect beyond the injection site. Treatment responses as
seen on day 42 are summarized in Table II.
Three patients were still alive after the end of a 5 y follow-up
period. One patient (#6) was free of all melanoma metastases at 5 y
follow-up and had then reached complete remission. Of the other
two patients, one received only surgical therapy (excision of
cutaneous metastases) and one (patient #5) received additional
treatment with interferon-a2 (3 3 106 units three times a week for
1 y). Both are tumor free to date as shown by routinely performed
CT scans. Of the remaining four patients, one died free of
melanoma metastases at the age of 93 after receiving only surgical
treatment of localized metastases. The other three patients died due
to progressive melanoma. Taken together, this results in a mean
long-term survival of 33 mo after initiation of treatment. In our
small group of patients no relation of long-term survival to the
histologic type or the depth of invasion of the primary tumor could
be observed. There was also no relationship between lymph node
metastases excised prior to treatment and long-term survival (see
Table III).
r-GM-CSF treatment was well tolerated by all seven patients
leading only to mild drowsiness and local erythema at the injection
sites. White blood count was more than doubled in all patients after
intradermal injection of the ®rst dose of 400 mg r-GM-CSF and
rose to more than 20,000 during each 5 d treatment period
(22,700 6 8600; data not shown). A rise in eosinophils was also
observed with a mean peak level of 11.6% 6 4.4% in the relative
blood count.
Table I. Patients' characteristics
No. of patients entered 7
Male:Female 5 : 2
Mean age in years (range) 76.4 (45-90)
Primary melanoma NMM 4/7
ALM 1/7
occult 2/7
Cutaneous metastases 7/7
Lymph node metastases 3/7
Visceral metastases 0/7
Previous treatment Immunotherapy
(IL-2, alpha IFN)
3/7
Chemotherapy 2/7
Surgery 7/7
None 0/7
Table II. Clinical response after two cycles of r-GM-CSF treatment
Patient
number
Percent size change of
injected lesion
Total number of cutaneous
metastases prior to treatment
Total number of cutaneous
metastases after treatment
1 +69.3 ­ 91 62 ¯
2 ±19.0 ¯ 3 7 ­
3 ±100.0 ¯ 4 1 ¯
4 ±61.0 ¯ 33 14 ¯
5 ±84.4 ¯ 5 7 ­
6 ±100.0 ¯ 4 0 ¯
7 ±54.4 ¯ 16 12 ¯
Table III. Outcome after 5 y of follow-up and relation to prior lymph node metastasesa
Patient
number
Survival
time
(mo)
Tumor related
death
Yes/No
Tumor free at time of
death or end of
follow-up
Lymph node metastases
prior to treatment
Y/N
1 38 N Y N
2 62 - Y N
3 4 Y N Y
4 6 Y N N
5 58 - Y Y
6 58 - Y Y
7 5 Y N N
aY, yes; N, no.
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Immunohistochemical analysis Treatment with r-GM-CSF
did not alter the expression of the GM-CSF receptor (GM-CSF-R)
on HMB-45-positive melanoma cells in any of the seven patients
investigated (Table IV). The number of CD14-positive
monocytes/macrophages within the tumor was increased about
3-fold by treatment with GM-CSF and the same was true for GM-
CSF-R in the investigated samples. This increase in GM-CSF-R is
probably due to the increased number of CD14-positive cells of the
monocyte/macrophage lineage, but we cannot exclude an increase
in receptor density per CD14-positive cell as the reason for this
increased staining. In addition, a high increase of CD4-positive
lymphocytes and a moderate increase of CD8-positive lymphocytes
in the tumor lesions were observed. We want to stress that no
immunohistochemical differences between injected indicator
lesions and reactions in distant metastases exposed only
systemically to r-GM-CSF were observed (Table IV). All
stainings with isotype controls remained negative.
DISCUSSION
Improved antitumor strategies have altered the prognosis of a
variety of human malignancies. Metastatic melanoma remained one
of the notable exceptions, however, despite the known immuno-
genicity of this tumor (Avril et al, 1992; Balch et al, 1992; Blessing
and McLaren, 1992). A number of studies have demonstrated that
the host response to tumor challenge can be decisively in¯uenced
by the inoculation of tumor cells genetically engineered to express
cytokines, in particular GM-CSF (Dranoff et al, 1993; Pardoll,
1993; Armstrong et al, 1996). Dranoff et al found GM-CSF, most
often associated with growth and differentiation of hematopoietic
progenitors, to be the most powerful of 10 molecules tested.
In this study we describe the effect of intracutaneous GM-CSF
on stage IV patients with cutaneous melanoma metastases. One
complete remission was obtained and three of seven patients are still
alive at 5 y without any other further treatment than surgical
removement of metastases and, in one patient, 1 y of interferon a2.
One patient died tumor free due to cardiovascular disease after also
receiving only surgical treatment of residual metastases. Thus GM-
CSF administration resulted in a mean survival of 33 mo after
initiation of treatment; survival is still 28.8 mo if one excludes from
evaluation patient #5 for receiving an additional therapy with
interferon-a. In advanced melanoma surgical treatment alone
results in a median survival of 15.7 mo (Brand et al, 1997).
If one compares the response of the individual patients on day 42
(end of the second treatment period) with the long-term results
(Table II versus Table III), there is no uniformity of response. For
example, patient #2 initially even had an increase in the number of
metastases with a slight decrease in the size of the indicator lesion
but is one of three patients still alive with only surgical treatment
after GM-CSF therapy. This implies that a systemic effect induced
by locally injected GM-CSF seems to be more relevant for long-
term survival than the initial local response. The nature of a possible
predictive factor for therapeutic susceptibility to GM-CSF therapy
remains unclear as already discussed elsewhere (Si et al, 1996).
In our study, intracutaneous GM-CSF treatment caused an
in®ltration of all the investigated cutaneous melanoma lesions by
cells of the monocytic and lymphoid lineage leading to a decrease
in the total number of metastases in all but two patients, and a
decrease in the size of the indicator lesion in all but one patient.
This differs from the results of other studies, but these were short
term and doses of GM-CSF employed were different. In a study by
Si et al on 13 patients with at least three subcutaneous melanoma
metastases injected intralesionally with GM-CSF only three patients
showed a partial regression of the lesions and only four of 11
evaluable patients showed an increase of T cells and macrophages
around the metastases. Si et al, however, used a dose of 15-50 mg
per d delivered intralesionally in contrast to the 400 mg delivered
perilesionally in our study. Robinson et al (1998) applied GM-CSF
continuously intralesionally by using a pump system with a dose of
10 mg per 24 h and observed a partial response in one of eight
patients. GM-CSF was also used as an aerosol in patients with lung
metastases including one patient suffering from melanoma
metastases who showed a partial regression of his lesions
(Anderson et al, 1999). All these data come from short-term
studies, however, and to date no comparable 5 y follow-up data
exist.
As Dranoff et al (1993) showed that irradiated tumor cells
expressing GM-CSF were capable of protecting mice more
effectively against subsequent tumor inoculation than tumor cells
alone, efforts have been undertaken to develop therapeutic
strategies using GM-CSF together with peptide vaccines or
tumor cells in various combinations. Leong et al (1999) applied r-
GM-CSF together with an autologuos melanoma vaccine and
observed regression of all tumor lesions in 10% of their patients and
a partial response in another 10%. Soiffer et al (1998) used GM-
CSF-expressing irradiated melanoma cells for vaccination and
observed a high degree of in®ltration with T cells and destruction
of metastases by up to 80% of the initial lesional volumes. A recent
study by Mastrangelo et al (1998) employed a vaccinia virus system
to transfect GM-CSF encoding c-DNA into melanoma metastases.
In their study they found regression of the injected lesions and also
regression of distant metastases comparable to the reaction pattern
seen in our patients. One can argue that these vaccination strategies
have a higher potential in inducing antitumor immunity but a
major problem with the strategies is that they are technically
dif®cult to apply, need a specialized center, and therefore are
available only for a limited number of patients. On the other hand
intradermal GM-CSF administration is easy to perform.
Additionally a recent study in melanoma patients using GM-CSF
in an adjuvant setting showed prolongation of overall and disease-
free survival (Spitler et al, 2000) and further supports the potentials
of GM-CSF in melanoma therapy.
Taken together, the data provided in this work show that GM-
CSF applied intracutaneously and perilesionally appears as a
promising, easily applicable, and well tolerated therapeutic strategy
for patients with skin metastases of malignant melanoma. GM-CSF
seems to augment host anti-melanoma immunity and to provide
favorable long-term results. Follow-up studies with larger groups of
patients will clearly be needed to learn more about optimal dosage,
treatment schedules, and potential combinations with other
therapeutic strategies to optimize treatment outcome.
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